Madison Vaccines expands investigational prostate cancer vaccines
These changes will occur in the company’s early, advanced and late-stage prostate cancer vaccine programs. With MVI’s advanced prostate cancer program, the Food and Drug Administration has approved of the application for a Phase 1 Investigational New Drug study for MCI-118. This vaccine is meant to treat the progression and resistance of the cancer.
For non-metastatic prostate cancer, the company has opened two additional enrollment sites for its Phase 2 clinical trial of MCI-816. For late-stage prostate cancer, MVI has created a trial that combines treatments of MCI-816 with a PD-1 inhibitor.
MVI has made changes to its financing to fund these projects, including raising its Series A financing to $11 million.
“MVI is now uniquely positioned with our product-candidates in three distinct stages of prostate cancer from pre-metastatic to the start of metastases to late-stage, castrate-resistant disease,” MVI President Richard Lesniewski said. “We believe our products can make a meaningful difference in treating this disease, and we are pleased to have the expertise of Douglas McNeel, M.D., Ph.D., our scientific co-founder and a leading prostate cancer researcher at the University of Wisconsin-Madison.”